Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization

Anke Fuchs 1 Mateusz Gliwiński 2 Nathali Grageda 3 Rachel Spiering 4 Abul Abbas 5 Silke Appel 6 Rosa Bacchetta 7 Manuela Battaglia 8 David Berglund 9 Bruce Blazar 10 Jeffrey Bluestone 5 Martin Bornhäuser 1 Anja ten Brinke 11 Todd Brusko 12 Nathalie Cools 13, 14 Maria Cuturi 15 Edward Geissler 16 Nick Giannoukakis 17 Karolina Gołab 18 David Hafler 19 S Marieke van Ham 11 Joanna Hester 20 Keli Hippen 10 Mauro Di Ianni 21 Natasa Ilic 22 John Isaacs 4, 23 Fadi Issa 20 Dorota Iwaszkiewicz-Grześ 2 Elmar Jaeckel 24 Irma Joosten 25 David Klatzmann 26 Hans Koenen 25 Cees van Kooten 27 Olle Korsgren 28, 29 Karsten Kretschmer 30, 31 Megan Levings 32 Natalia Marek-Trzonkowska 2 Marc Martinez-Llordella 3 Djordje Miljkovic 22 Kingston Mills 33 Joana Miranda 34 Ciriaco Piccirillo 35 Amy Putnam 5 Thomas Ritter 36 Maria Roncarolo 37 Shimon Sakaguchi 38 Silvia Sánchez-Ramón 39 Birgit Sawitzki 40 Ljiljana Sofronic-Milosavljevic 22 Megan Sykes 41 Qizhi Tang 5 Marta Vives-Pi 42 Herman Waldmann 20 Piotr Witkowski 43 Kathryn Wood 20 Silvia Gregori 8 Catharien Hilkens 4 Giovanna Lombardi 3 Phillip Lord 4 Eva Martinez-Caceres 42, 44 Piotr Trzonkowski 2
15 Team 1 - U1064 Inserm - CRTI - Dendritic cells and immunoregulation in transplantation and immunopathology
U1064 Inserm - CRTI - Centre de Recherche en Transplantation et Immunologie
Abstract : Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02157859
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Monday, June 17, 2019 - 3:00:38 PM
Last modification on : Friday, October 25, 2019 - 8:50:03 AM

File

fimmu-08-01844.pdf
Publication funded by an institution

Identifiers

Citation

Anke Fuchs, Mateusz Gliwiński, Nathali Grageda, Rachel Spiering, Abul Abbas, et al.. Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Frontiers in Immunology, Frontiers, 2018, 8, ⟨10.3389/fimmu.2017.01844⟩. ⟨inserm-02157859⟩

Share

Metrics

Record views

146

Files downloads

69